Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Zevra Therapeutics, Inc. - Common Stock (NQ:ZVRA)

9.005 -0.195 (-2.12%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Zevra Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Crude Oil Down 1%; Performance Food Group Earnings Top Views
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Top movers in Wednesday's session
Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.
Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations. 
Via Investor's Business Daily
A Look at Zevra Therapeutics's Upcoming Earnings Report
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Beyond The Numbers: 7 Analysts Discuss Zevra Therapeutics Stock
 
Via Benzinga
Wednesday's session: gap up and gap down stocks
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Zevra Revenue Jumps 486 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
Zevra Therapeutics Mixed Q2 Results: Details
Zevra Therapeutics reported its second-quarter financial results Tuesday. Here's a look at the details. 
Via Benzinga
Earnings Scheduled For August 12, 2025
 
Via Benzinga
How Zevra's Miplyffa Could Transform Investment Strategies
HC Wainwright sees Zevra's Miplyffa launch and EU plans driving upside, initiating coverage with a $26 target and Buy rating on rare disease strength. 
Via Benzinga
This Block Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
 
Via Benzinga
Breaking Down Zevra Therapeutics: 6 Analysts Share Their Views
 
Via Benzinga
Zevra Therapeutics (ZVRA) Stock Jumps on Strong Q1 Results: What's Going On?
Zevra Therapeutics shares are trading higher by 6.7% Wednesday morning. The company reported better-than-expected Q1 financial results. 
Via Benzinga
Zevra Therapeutics's Earnings Outlook
 
Via Benzinga
Earnings Scheduled For May 13, 2025
 
Via Benzinga
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a... 
Via Stocktwits
Topics Stocks
Zevra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)
 
Via Benzinga
Earnings Scheduled For March 11, 2025
 
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Zevra Therapeutics' Drug Becomes First FDA-Approved Treatment For Ultra-Rare Neurodegenerative Disease
The FDA has approved Zevra Therapeutics' Miplyffa (arimoclomol) as the first treatment for neurological symptoms of Neimann-Pick disease, type C. This approval follows favorable voting by the Genetic... 
Via Benzinga
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
ZVRA Stock Earnings: Zevra Therapeutics Misses EPS, Beats Revenue for Q2 2024
ZVRA stock results show that Zevra Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
PubMatic, Eventbrite, Five9 And Other Big Stocks Moving Lower In Friday's Pre-Market Session
 
Via Benzinga
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
FDA Panel Backs Zevra's Arimoclomol For Rare Genetic Disorder, Analyst Highlights Balanced Portfolio Of Marketed Products And Pipeline Assets Focused On Rare Diseases
FDA panel supports Zevra Therapeutics' arimoclomol for Niemann-Pick disease type C with an 11-5 vote. William Blair boosts success probability to 90%, highlighting Zevra's growth and balanced rare... 
Via Benzinga
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.